Valuation : ALLOVIRPAR

Market Cap 49.21M 42.31M 39.81M 36.33M 67.79M 4.67B 68.14M 472M 182M 2.38B 185M 181M 7.59B P/E 2023
-0.37x
P/E 2024 -0.82x
Enterprise Value -69.08M -59.39M -55.88M -50.99M -95.16M -6.55B -95.65M -662M -256M -3.35B -259M -254M -10.65B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
-
Yield 2023 *
-
Yield 2024 -
1 day-6.92%
Current month-63.00%
Current year-63.00%
3 years 3.6
Extreme 3.6
67.39
5 years 3.6
Extreme 3.6
607.43
10 years 3.6
Extreme 3.6
1,126.08

Financials

2023 2024
Net sales - -
Net income -190M -164M -154M -141M -262M -18.05B -264M -1.82B -706M -9.23B -715M -699M -29.36B -58.77M -50.53M -47.54M -43.38M -80.96M -5.57B -81.38M -563M -218M -2.85B -221M -216M -9.06B
Net Debt -157M -135M -127M -116M -216M -14.84B -217M -1.5B -580M -7.58B -588M -575M -24.13B -118M -102M -95.68M -87.32M -163M -11.21B -164M -1.13B -439M -5.73B -444M -434M -18.24B
Logo ALLOVIRPAR
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
Employees
6
Sector
-
Date Price Change
08/09/26 US$3.630 -6.92%
04/09/26 US$3.900 -1.02%
03/09/26 US$3.940 +1.03%
02/09/26 US$3.900 -0.51%
01/09/26 US$3.920 -2.97%
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB
  1. Stock Market
  2. Stocks
  3. ALVR Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!